Not sure about the treatment regimens. Can't see 177Lu-J591 (rosapatamab) being administered closer together - circulating radionuclide damages blood cells and also marrow (marrow toxicity is the major disadvantage for J591), so you need to leave enough time (weeks) for the body to replenish blood cells before re-treating. This already occurs with 177Lu-PSMA-617 (and other radionuclide therapies) spaced at 8 weeks.
617 has been studied much more widely than J591 - novartis did a good job getting the product out there and used in multicentre trials.
FYI there has been some interest in combining 617 and J591 therapies - even a phase I trial based in Weill Cornell (177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC - Full Text View - ClinicalTrials.gov)
- Forums
- ASX - By Stock
- Competition
Not sure about the treatment regimens. Can't see 177Lu-J591...
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$21.49 |
Change
-0.470(2.14%) |
Mkt cap ! $7.192B |
Open | High | Low | Value | Volume |
$22.26 | $22.38 | $21.44 | $26.56M | 1.224M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 5461 | $21.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.61 | 172 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5461 | 21.470 |
2 | 3362 | 21.460 |
2 | 1500 | 21.450 |
3 | 2667 | 21.440 |
1 | 3857 | 21.430 |
Price($) | Vol. | No. |
---|---|---|
21.610 | 172 | 1 |
21.640 | 1030 | 2 |
21.680 | 9989 | 1 |
21.700 | 5825 | 2 |
21.730 | 3857 | 1 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online